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Abstract
Antiviral drug resistance for influenza therapies remains a concern due to the high prevalence of H1N1 2009 seasonal
influenza isolates which display H274Y associated oseltamivir-resistance. Furthermore, the emergence of novel H1N1 raises
the potential that additional reassortments can occur, resulting in drug resistant virus. Thus, additional antiviral approaches
are urgently needed. DAS181 (FludaseH), a sialidase fusion protein, has been shown to have inhibitory activity against a
large number of seasonal influenza strains and a highly pathogenic avian influenza (HPAI) strain (H5N1). Here, we examine
the in vitro activity of DAS181 against a panel of 2009 oseltamivir-resistant seasonal H1N1 clinical isolates. The activity of
DAS181 against nine 2009, two 2007, and two 2004 clinical isolates of seasonal IFV H1N1 was examined using plaque
number reduction assay on MDCK cells. DAS181 strongly inhibited all tested isolates. EC50 values remained constant against
isolates from 2004, 2007, and 2009, suggesting that there was no change in DAS181 sensitivity over time. As expected, all
2007 and 2009 isolates were resistant to oseltamivir, consistent with the identification of the H274Y mutation in the NA
gene of all these isolates. Interestingly, several of the 2007 and 2009 isolates also exhibited reduced sensitivity to zanamivir,
and accompanying HA mutations near the sialic acid binding site were observed. DAS181 inhibits IFV that is resistant to
NAIs. Thus, DAS181 may offer an alternative therapeutic option for seasonal or pandemic IFVs that become resistant to
currently available antiviral drugs.
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Introduction
On the global scale, ‘‘classical’’ seasonal influenza results in
250,000–500,000 deaths and three to five million cases of severe
illness annually [1]. Yearly vaccination is important for preventing
influenza virus (IFV) infection. However, because of antigenic shift
and antigenic drift, and the guesswork involved in predicting the
dominant strains in future seasons, vaccines need to be updated
every year and may not always be protective. Furthermore,
production challenges for novel viruses or multi-strain epidemics
threaten the supply of needed vaccine (e.g. current pandemic
vaccine efforts reducing seasonal vaccine production). Finally, the
host protective immune response may not be adequate in certain
populations. Antiviral compounds are therefore needed for treating
infected individuals, particularly during a severe or novel IFV
outbreak. A well-recognized limitation of currently available
antivirals is the risk of development of drug resistance. The
emergence of drug-resistant IFV strains is a major public health
concern in light of the burden of seasonal influenza and the ongoing
pandemic of the 2009 A(H1N1) virus. The predicament of antiviral
resistance is evident in the rapid establishment of viral resistance to
M2 inhibitors (adamantanes) and the dramatic rise of oseltamivir-
resistant seasonal H1N1 influenza in recent years [2–8].
While neuraminidase inhibitor (NAI)-resistance has been ob-
served to occur via different molecular mechanisms [9], the
dominating change conferring oseltamivir-resistance in the current
seasonal IFV is a mutation in the neuraminidase (NA) gene, H274Y.
This mutation has been also observed in oseltamivir-treated patients
infected with the H5N1 HPAI, a troubling observation given the
pandemic potential and extremely virulent nature of this IFV strain
[10–12]. The frequency of isolates with the H274Y mutation has
increased with each flu season, including in countries that do not
regularly prescribe oseltamivir [2,5–7]. According to CDC reports,
the frequency of oseltamivir-resistance in seasonal isolates of H1N1
collected in USA grew from less than 0.5% in 2006–2007, to 13%
in 2007–2008, to 99% in 2008–2009 (http://www.cdc.gov/flu/
weekly/weeklyarchives2008-2009/weekly15.htm). Interestingly, this
H274Y mutation was once believed to confer reduced viral fitness.
However, because of the ease of transmission and significant
pathogenicity in high risk patients, it is now concluded that the
current oseltamivir-resistant H274Y mutantlikelypossessesthe same
degree of virulence as the wild-type strain [2,6,13]. Novel classes of
anti-IFV compounds are needed, in particular to combat strains
resistant to current drugs [14].
DAS181 (FludaseH) is a recombinant fusion protein composed
of the catalytic domain of Actinomyces viscosus sialidase and the
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efficiently binds to respiratory epithelial cells and then removes
cell-surface sialic acid residues [15,16]. Sialic acid is the receptor
which mediates IFV binding and entry into the host cell; therefore,
removal of sialic acid by DAS181 potently inhibits IFV infection
[15,17]. By targeting the host cells rather than the virus, DAS181
may be less likely to induce drug resistance than virus-targeting
compounds (e.g. adamantanes and NAIs). Long term DAS181
exposure to numerous cell lines and human primary cells does not
cause cytotoxicity (Figures S1-2 and Methods S1). In numerous
animal studies, as well as in ongoing phase 1 clinical trials,
DAS181 is well-tolerated ([15] and unpublished data). In guinea
pig and mouse asthma models, DAS181 does not cause airway
hyperreactivity (unpublished data).
DAS181 has previously been reported to inhibit a large number
of laboratory IFV strains and some clinical isolates both in vitro and
in vivo [15,18]. Here we report activity of DAS181 against a panel
of seasonal IFV clinical isolates from recent seasons that are
resistant to oseltamivir. A number of the 2009 seasonal IFV
clinical isolates also exhibited changes in the HA that potentially
reduced the virus’ dependence on NA activity for virus release.
Those clinical isolates exhibited decreased sensitivity in the
MDCK cell assay to both NAIs, oseltamivir and zanamivir.
Results
To evaluate activity of DAS181 against recent clinical isolates
expected to be resistant to oseltamivir, we obtained nine seasonal
IFV H1N1 isolates collected from patients at St. Louis University
in the months of January and February of 2009. For comparison
we obtained from CDC two pairs of seasonal IFV reference
viruses: one pair is sensitive to both NAIs (2004 isolates) and the
other pair is resistant to oseltamivir, due to the H274Y mutation in
the NA (2007/08 season isolates, representative of two distinctive
clades, ‘‘Hawaiian’’ and ‘‘Northern European’’). The 2004 H1N1
clinical isolates were presumed to be oseltamivir sensitive, since no
oseltamivir-resistance has been reported in community isolates
prior to 2007. All isolates were tested for sensitivity to DAS181
using the plaque number reduction assay (PRA) with MDCK cells.
The NAIs oseltamivir and zanamivir were also tested in tandem as
controls. EC50s for each drug were calculated for each strain and
compared to the 2004 strains in order to estimate fold resistance.
Dose response curves of the 2004, 2007, and 2009 isolates
showed reduced sensitivity to oseltamivir and varied sensitivity to
zanamivir in the 2009 isolates (Figure 1). Quantification revealed
that EC50 values of oseltamivir against the 2007 and 2009 isolates
were .100 times higher than that against the 2004 isolates
(Table 1), indicating over 100-fold drug resistance for the 2007
and 2009 isolates in MDCK cells. Interestingly, EC50 values of
zanamivir appeared to be elevated against 4 of the 9 isolates from
2009 (Table 1). All of the IFV clinical isolates were highly sensitive
to DAS181 (Figure 1, Table 1). EC50 values of DAS181 were
similar against each of the 2004, 2007, and 2009 isolates (Table 1).
Of note, 3 of the 4 isolates from 2009 that appeared to have
reduced sensitivity to both NAIs were approximately 10-fold more
sensitive to DAS181 in MDCK cells (Table 1).
Upon sequencing the neuraminidase (NA) gene of the clinical
isolates, we found that all of the tested 2007 and 2009 isolates, but
not the 2004 isolates, contained the NA H274Y mutation known to
confer oseltamivir resistance.Noadditional mutation inthe NAgene
was found that was specific to each of the isolates with apparently
reduced zanamivir sensitivity. An N32S mutation was found in all
but one zanamivir-sensitive 2009 isolate (A/St.Louis/758/09) and
an I222V mutation was observed solely in two zanamivir-resistant
2009 isolates (Figure S3 and S4). We further characterized the
NAI-resistance of the 2009 isolates by the NA activity inhibition (NI)
assay, which measures the NA enzymatic activity in the presence of
oseltamivir or zanamivir. In the NI assay, oseltamivir failed to
effectively inhibit NA activity from each of the 2007 and 2009
isolates; however, all of these isolates were equally sensitive to
zanamivir, including the 2009 isolates that carry the N32S and
I222Vmutations(Table 2).Thus,theNAactivityofthe2009isolates
is still effectively inhibited by zanamivir, consistent with the lack of
NA mutations specific to all the isolates that are less sensitive to
zanamivir.
To further characterize the observed reduction in zanamivir
sensitivity exhibited by some of the isolates on the PRA, we also
performed sequence analysis of the HA gene in all of the isolates.
Mutations at one of two positions in the HA gene, N163 and D225,
were observed only in the viral isolates with reduced zanamivir
sensitivity (Table 3, full alignment Figure S5). Non-conserved
mutations at these two positions, N163K/H and D225G, thus may
be sufficient to cause reduced sensitivity to NAIs in MDCK cells.
Although a zanamivir-sensitive isolate, A/St.Louis/758/09, carries
a N163T mutation, this isolate also has a unique, nearby V189A
mutation that might negate the effects of the N163T mutation such
that the virus remains sensitive to zanamivir (Table 3). Sequence
alignment with a published IFV A H1 crystal structure reveals that
N163, D225, as well as V189 lie near the sialic acid binding pocket
of HA (Figure 2). Therefore, the observed mutations might affect
receptor binding affinity of the HA protein in MDCK cells.
Discussion
Two classes of antivirals against IFV are currently on the
market, the adamantanes (amantadine and rimantadine), and the
NAIs (oseltamivir and zanamivir). Antivirals play an important
role in the treatment of severe seasonal and pandemic influenza,
but their effectiveness is limited by the potential for IFV to develop
drug resistance. Fortunately, the current pandemic IFV strain of
swine origin (2009 A (H1N1)) is still largely sensitive to oseltamivir,
although it is resistant to adamantanes [19]. However, given the
presence of rampant oseltamivir resistance among the current
seasonal H1N1 IFV strains, it could be just a matter of time before
the pandemic H1N1 virus acquires resistance to oseltamivir [20].
Indeed, 28 cases of 2009 A (H1N1) resistance to oseltamivir have
been reported as of October 2, 2009 (http://www.who.int/csr/
don/2009_10_02/en/index.html). Thus development of novel
therapeutics with unique mechanism of action is of great im-
portance to public health.
In our analysis, all eleven 2007 and 2009 seasonal IFV clinical
isolates (11/11) exhibited resistance to oseltamivir when tested in
MDCK cells. The high frequency of observed oseltamivir resistance
and H274Y mutation in our 2009 H1N1 isolates correlates with
worldwide reports of resistance in this season(http://www.cdc.gov/
flu/weekly/weeklyarchives2008-2009/weekly15.htm). Here we re-
port that DAS181 is a potent inhibitor of the recent IFV clinical
isolates. There is no reduction in DAS181 sensitivity amongst all the
tested IFV clinical isolates from 2004, 2007 and 2009, demonstrat-
ing that the H274Y mutation does not reduce DAS181 sensitivity.
It has been well established that IFV develops resistance to NAIs
through two mechanisms: one, mutations in NA that decrease
binding affinity to NAI drugs, such as the H274Y mutation in the
current seasonal IFV; two, mutations in HA which decrease virus
receptor binding affinity, thereby reducing dependence on NA [9].
While NA mutations tend to make IFV resistant to one NAI drug,
HA mutations have the potential to confer resistance to all NAI
drugs. However, it is essential to recognize that NAI resistance
DAS181 Inhibits Resistant IFV
PLoS ONE | www.plosone.org 2 November 2009 | Volume 4 | Issue 11 | e7838Figure 1. In vitro sensitivity of recent clinical isolates to oseltamivir, zanamivir and DAS181. Confluent MDCK cells were infected with
clinical isolates of IFV A (H1N1) (from 2004, 2007, or 2009) and drug sensitivity was determined by plaque reduction assay (PRA). The number of viral
plaques with each drug concentration was counted and plaque number was normalized against the untreated control. The graphs shown here
represent a single PRA from a subset of all viruses tested (Table 1). The last two digits of each virus name indicate the year it was collected.
doi:10.1371/journal.pone.0007838.g001
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reduce the virus binding to receptors in one host (e.g., MDCK
cells) may not be the same that produce such effect in another host
(e.g., humans). Therefore, viruses that show ‘‘pan-NAI resistance’’
in MDCK cells could be fully susceptible to NAI in humans and
vice versa [21–23]. HA mutations may play a role in reduced
susceptibility to NAIs in drug patients, although direct experi-
mental evidence is lacking at this time. In addition to resistance
issues, HA mutations can change the tropism of viral binding
(upper vs. lower respiratory tract binding) and the antigenicity of
the virus.
When HA sequence analysis was performed on viruses
recovered from oseltamivir treated children, an HA S262N
mutation was found in 1 out of 50 cases, but NA mutations were
detected in 18% of the cases [24]. Additional HA mutations, with
or without accompanying NA mutations, have also been reported
in other studies [21,25–28]. In spite of numerous HA mutations
reported in clinical samples, there is a lack of documentation on
HA-mediated resistance to NAI drugs in seasonal IFV due to the
lack of an acceptable phenotypic assay that can be used for
surveillance purpose and resistance diagnosis [9]. The commonly
used MDCK cell PRA is considered unreliable for detecting NAI
resistance in humans because it is prone to give false positive and
false negative results [9]. The well differentiated human airway
epithelium culture (HAE) is an experimental model system that
better mimics the human airway, but it is cumbersome to grow
and IFV clinical isolates tend to grow poorly in HAE cultures.
Thus, the best option to identify HA mutations that may
potentially give rise to NAI resistance may be to perform sequence
analysis of the HA gene to specifically look for mutations at or near
sialic acid binding site [9].
In the 2007 and 2009 clinical isolates that appear to have
decreased sensitivity to zanamivir based on PRA, we have
identified mutations involving two amino acid residues in the
HA gene that are proximate to the sialic acid binding site, N163
and D225. Mutation of N163 may be highly relevant for NAI-
resistance because glycosylation of asparagine (N) near the sialic
binding site directly impacts the HA receptor binding affinity
[29,30]. Mishin et al. reported that introduction of an N163G
mutation made a recombinant laboratory IFV strain more
sensitive to NAIs in MDCK cells [31]. However in our analysis,
the N163H/K/T mutation was primarily observed in isolates with
reduced zanamivir sensitivity, which seems to indicate an opposite
effect of mutation involving N163. This contradiction may be due
to differences in the HA backbone sequence between the isolates
tested here and the virus in Mishin et al. It also reflects the
complexity of interpreting HA mutations. Nevertheless, these
results together suggest significance of N163 residue in NAI
sensitivity in MDCK cells.
Examination of the HA sequence of pandemic 2009 IFV finds
that nearly all isolates have a lysine (K) at amino acid 163, yet
exhibit normal zanamivir sensitivity. However, the framework
sequence of the HA in the pandemic 2009 IFV is radically
different from that of seasonal H1N1 IFV, and thus inferences
Table 1. In Vitro sensitivity of recent clinical isolates to NAIs
and DAS181.
Virus
(Year isolated in bold)
EC50 oseltamivir
(uM)
EC50 zanamivir
(uM)
EC50 DAS181
(uM)
A/HongKong/2637/04 3.2761.32 1.8260.46 0.4960.06
A/HongKong/2765/04 2.9261.00 4.1760.53 0.2660.13
A/NewJersey/15/07 .400 7.0262.46 0.2060.01
A/Hawaii/21/07 .285 45.03622.53 0.2960.02
A/St.Louis/539/09 .400 .332 0.02060.001
A/St.Louis/746/09 .400 1.9660.42 0.7560.20
A/St.Louis/775/09 .320 1.2060.36 0.2560.06
A/St.Louis/758/09 .400 7.0662.84 0.0960.03
A/St.Louis/630/09 .400 62.10634.84 0.1460.02
A/St.Louis/764/09 .400 .273 0.03060.002
A/St.Louis/690/09 .400 .182 0.5160.14
A/St.Louis/790/09 .304 3.1261.83 0.2860.06
A/St.Louis/792/09 .400 .156 0.0460.01
Values represent mean6SEM of triplicate plaque number reduction assay (PRA)
experiments.
doi:10.1371/journal.pone.0007838.t001
Table 2. Sensitivity of the 2009 clinical isolates to NAIs based on NA enzymatic activity.
Category Virus Oseltamivir IC50 (nM) R/S Zanamivir IC50 (nM) R/S
Reference virus A/Georgia/17/2006 WT 0.37 S 0.44 S
A/Georgia/20/2006 H274Y 192.42 R 0.57 S
A/New Jersey/15/2007 123.54 R 0.49 S
A/Hawaii/21/2007 109.53 R 0.43 S
2009 clinical isolate A/St.Louis/539/09 84.92 R 0.28 S
A/St.Louis/746/09 89.93 R 0.3 S
A/St.Louis/775/09 91.85 R 0.33 S
A/St.Louis/758/09 88.41 R 0.34 S
A/St.Louis/630/09 224.37 R 0.48 S
A/St.Louis/764/09 102.82 R 0.3 S
A/St.Louis/690/09 178.37 R 0.44 S
A/St.Louis/790/09 87.82 R 0.29 S
A/St.Louis/792/09 91.47 R 0.28 S
The 2006 and 2007 viruses (top 4) were included as reference strains.
S=Sensitive to drug. R=Resistant to drug.
doi:10.1371/journal.pone.0007838.t002
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tenuous at best. For seasonal influenza H1N1 an alignment of 2009
sequences prior to the swine flu outbreak (01/2009 to 03/2009)
reveals that 85/89 have an N and 2/89 have K/H/T at amino
acid 163, indicating that the N163K/H/T mutation is rare, but
does exist at some low level in seasonal influenza (Influenza Virus
Resources, [32]). Further, most testing of NAI sensitivity currently
occurs with the NI assay, which would miss NAI-resistance due to
HA mutations, and limited prescription of zanamivir might reduce
the chance of observing clinical zanamivir resistance. Hence,
N163K/H/T-mediated reduction in NAI sensitivity in humans is
unlikely to have been observed as yet.
An NA mutation (I222V) was observed in two of the zanamivir-
resistant 2009 seasonal IFV strains, in addition to the well described
H274Y mutation. Interestingly this mutation has recently been
observed, in tandem with the H274Y mutation, in 2 patients with
pandemic 2009 IFV. Drug sensitivity analysis was not performed on
these viral isolates, therefore the significance of the I222V mutation
in patients is unclear [33]. Previous in vitro selection studies have
indicated that the I222V mutation exacerbates oseltamivir- and
peramivir-resistance caused by H274Y, but has only modest affect
on zanamivir sensitivity [34,35].
Broad-spectrum resistance to NAIs caused by a combination of
HA and NA mutations has been previously reported when
laboratory IFV strains were subjected to in vitro passages in the
presence of oseltamivir [36] or peramivir [37]. In the first case, a
combination of A28T(HA) and R292K(NA) mutations resulted in
3230-fold and 60-fold resistance by A/Victoria/3/75 (H3N2) to
oseltamivir and zanamivir, respectively [36]. In the second case,
B/Yamagata/16/88 acquired 100 to 700-fold resistance to
oseltamivir, zanamivir, and peramivir due to a H274Y mutation
in NA in combination with six HA mutations (G141E, D195N,
T197N, T139N, R162M, and Y319H) [37]. Similarly in our study,
the 2007 and 2009 isolates that are resistant to oseltamivir and have
reduced sensitivity to zanamivir carry mutations in both NA
(H274Y) and HA (N163K/T/H and D225G), but the observed HA
mutations have not been reported previously in drug-resistant IFV
strains. The N163 and D225 amino acids are highly conserved
amongst published H1N1 IFV strains (Figure S6), further indicating
their potential importance in viral infection. Further elucidation in
in vivo models is required to confirm the clinical significance of these
mutations. Finally, an IFV A/Victoria/3/75 passaged with
peramivir and found to be strongly pan-NAI resistant (oseltamivir,
zanamivir, peramivir) in vitro [38], correlating with a single HA
mutation (K186E), has been subsequently shown to be highly
sensitive to DAS181 in MDCK cells and mice (unpublished data).
Distinct from the adamantanes and NAIs, DAS181 targets the
host cells, not the virus. It functions by removing sialic acid
receptors for IFV and thus rendering the host cells unable to be
infected by IFV. Given the unique mechanism of action of
DAS181, it is not unexpected that IFV strains that are resistant to
antivirals remain sensitive to DAS181. Our results suggest that
DAS181 could be an effective treatment for NAI-resistant IFV,
whether the drug resistance is due to mutations in NA or HA. We
have previously demonstrated that DAS181 potently inhibits the
current pandemic H1N1 virus of swine origin in vitro and in vivo
[39]. Thus, DAS181 may offer a potential therapeutic option for
pandemic 2009 A(H1N1) virus resistant to NAI drugs.
Materials and Methods
Cells and Viruses
Madin Darby Canine Kidney (MDCK) cells were obtained
from American Type Culture Collection (Manassas, VA). The
2004 and 2007 seasonal IFV clinical isolates were obtained from
Alexander Klimov, Centers for Disease Control and Prevention.
The 2009 clinical isolates of seasonal IFV collected in the months
of February and March 2009 at Saint Louis University Hospital,
(A/St.Louis/XXX/09) were generously provided by Robert
Belshe, School of Medicine, Saint Louis University. Patient
information was confidential and no additional medical or
personal information was collected.
Viral Titer Determination by Plaque Assay
All 2009 clinical isolates were amplified for 3 passages on
MDCK cells after collection from human subjects before use in
this study. All viruses used here were initially quantified on
MDCK cells to determine infectious titer (plaque forming units per
Table 3. Hemagglutinin (HA1) mutations specific to isolates with reduced zanamivir sensitivity.
Virus EC50 Zanamivir (mM) Amino Acid at Position 163 Amino Acid at Position 189 Amino Acid at Position 225
A/HongKong/2637/04 1.8260.46 N V D
A/HongKong/2765/04 4.1760.53 N V D
A/NewJersey/15/07 7.0262.46 N V D
A/Hawaii/21/07 45.03622.53 K VD
A/St.Louis/539/09 .332 N V D/G
A/St.Louis/746/09 1.9660.42 N V D
A/St.Louis/775/09 1.2060.36 N V D
A/St.Louis/758/09 7.0662.84 TAD
A/St.Louis/630/09 62.1634.84 N V D/G
A/St.Louis/764/09 .273 H VD /G
A/St.Louis/690/09 .182 N/T VD
A/St.Louis/790/09 3.1261.83 N V D
A/St.Louis/792/09 .156 N V D/G
Each 2009 isolate was sequenced directly following three passages in MDCK cells, without plaque purification. Sequence heterogeneities were observed at some
locations and alternate amino acids at such locations are shown in the table. Amino acids different from reference strains are noted in bold. Sequence data noted with
H3 numbering scheme, as previously described [42].
doi:10.1371/journal.pone.0007838.t003
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the viral samples followed by 1 hr binding at 37uC on confluent
MDCK cells in 6-well plate format. After washing off unbound
virus with PBS, the cells were overlaid with 1:1 Noble Agar (1.8%)
and 2x DME-F12 (supplemented with Glutamax (Invitrogen,
Carlsbad, CA), ITS (Invitrogen), and 3 mg/ml acetylated trypsin
(Sigma, St. Louis, MO)). After allowing agar to solidify, the plates
were incubated for ,60 hrs at 37uC before fixing with crystal
violet and counting plaque number at each dilution.
Antiviral Compounds
Zanamivir (Relenza) was removed from Rotadisk blister packs
(each containing 5 mg of active zanamivir and 20 mg of lactose as
excipient) and reconstituted in deionized water with final
zanamivir concentration of 10 mM. Tartrate salt of oseltamivir
carboxylate (active form of Tamiflu) was generously provided by
F.Hoffmann-La Roche (Basel, Switzerland) and reconstituted in
deionized water such that the final oseltamivir carboxylate
concentration was 10 mM. Reconstituted NAIs were stored at
220uC until use. Purified DAS181 was supplied in 1.7 mM
acetate buffer, pH 5 and stored at 280uC until use.
Drug Sensitivity Testing with Seasonal IFV Strains
The clinical isolates of seasonal IFV were tested for DAS181
sensitivity simultaneous with oseltamivir and zanamivir sensitivity
using the plaque number reduction assay on MDCK cells. This
protocol is modified from previous publication [40]. In short 150
pfu of virus are applied to each well of confluent MDCK cells in
6-well plate format. After binding for 1.5 hrs, unbound virus is
washedoffwith PBSandthe platesareoverlaid with1:1NobleAgar
and DME-F12 as in the plaque assay. 2x DAS181, oseltamivir, or
zanamivir concentrations are included in the 2xDME-F12, so as to
achieve 1x final concentration in the agar/media mix. NAIs were
tested at concentrations from.04 to 400 mM, while DAS181 was
tested at concentrations from.0048 to 3 mM since no plaques
remained with 3 mM DAS181. After allowingagar to cool the plates
were incubated, stained, and counted as in the plaque assay. Data
was graphed as plaque number per drug concentration, normalized
tonodrug andexpressedaspercent plaquesremaining.EC50swere
calculated as the concentration of drug reducing plaque number to
50% of no drug control. All viruses were tested in triplicate against
each drug and values are represented as mean6SEM. All data was
graphed with Prism 4.02 software.
Figure 2. Location of hemagglutinin mutations specific to isolates with reduced zanamivir sensitivity. The amino acid positions for the
mutations listed in Table 3 were located on the published crystal structure of an IFV A H1 trimer (1RU7). Amino acid 163 is shown in red, 189 in green,
and 225 in blue. Left panel shows a side view of the HA trimer (with sialic acid binding site on top and membrane-proximal region on bottom) and
right panel shows a top down view of the HA trimer. Approximate site of sialic acid binding is indicated with arrows and yellow shaded area.
doi:10.1371/journal.pone.0007838.g002
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All 2004, 2007, and 2009 clinical isolates tested here were
sequenced to determine the HA and NA genotypes. In brief, RNA
was purified from 50 uL of viral sample using using MagMAX-
96
TM Viral RNA isolation kit (Applied Biosystems). The RNA was
purified according to manufacturer’s instructions and eluted in
50 mL elution buffer. PCR was performed on the RNA with
primers to amplify the entire HA and NA genes (designed based
on alignment of several H1N1 viruses). Upon confirming
amplification of correct size band the PCR product was purified
with PCR purification kit (Qiagen, Valencia, CA) and sequenced
using the same forward and reverse primers. Oligonucleotide
sequences were aligned (comparing all strains or only all 2009
strains) using ClustalW2 software (http://www.ebi.ac.uk/Tools/
clustalw2/index.html) and sequence data noted with H3 or N2
numbering scheme, as previously described [41,42]. Alignments of
NA sequences are shown in Figure S3 and S4. Alignments of HA
sequences are shown in Figure S5 and S6. Positions of mutated
amino acids within crystal structure of HA trimer were determined
by comparison to a published IFV A/PuertoRico/8/34 H1 trimer
(1RU7) using PyMOL Software [43]. HA and NA nucleotide and
amino acid sequences for the A/St.Louis/XXX/2009 isolates
have been submitted in Genbank; Accession numbers for HA
sequences: GQ994954, GQ994955, GQ994956, GQ994957,
GQ994958, GQ994959, GQ994960, GQ994961, GQ994962.
Accession numbers for NA sequences: GQ994963, GQ994964,
GQ994965, GQ994966, GQ994967, GQ994968, GQ994969,
GQ994970, GQ994971.
NI Assay
The chemiluminescent neuraminidase activity inhibition (NI)
assay was conducted using a commercially available kit, NA-Star
(Applied Biosystems, Foster City, CA) as previously described [7].
Oseltamivir carboxylate and zanamivir were used at 10 half-log
dilutions (0.03 to 1000 nM). Values shown represent mean of
triplicate analysis.
Supporting Information
Methods S1 Materials and methods for Figures S1 and S2.
Found at: doi:10.1371/journal.pone.0007838.s001 (0.04 MB
DOC)
Figure S1 Effect of DAS181 on cell line proliferation. To
determine whether DAS181 affected cell proliferation, the growth
of several immortalized cell lines were monitored in the presence
and absence of 17 mM DAS181. A549 (A), MDCK (B), CACO-2
(C), or BEAS-2B (D) cell lines were first plated at subconfluent
density. After 24 hrs the growth media was replaced with media
containing DAS181, PBS, or cell culture medium alone and
placed back at 37uC to incubate for 10 days. Relative cell numbers
were determined daily by crystal violet staining. Values represent
mean6SD of six replicates. DAS181 or PBS treatments were not
significantly different from cell culture medium alone for any of
the cell lines, as determined by ANOVA with Bonferroni post-test.
Found at: doi:10.1371/journal.pone.0007838.s002 (0.06 MB PPT)
Figure S2 Cytotoxic effect of DAS181 on primary human renal
epithelial cells. Human renal proximal tubule cells and cortical
epithelialcellswereexposedtovariousconcentrationsofDAS181for
24 hrs and monitored for cell viability over 3 days (A–F) or exposed
to DAS181 for 72 hrs and immediately assayed for cell viability
(G–H). In all cases some cells were also exposed to PBS (vehicle
control), or 0.2% thimerosol or 1 mM cadmium chloride (CdCl2) as
positive controls for cell death. Cell viability was assessed by MTS
assay. In all cases, treatment with either thimerosol or CdCl2
resulted in significant reduction in cell viability, however with minor
exception, all DAS181 treatment levels/regimens were not signifi-
cantlydifferentfromPBS.Valuesrepresentmean6SEMoftriplicate
samples. *=P,0.05, ***=P,0.001; significantly different from
PBS as determined by ANOVA with Bonferroni post-test.
Found at: doi:10.1371/journal.pone.0007838.s003 (0.37 MB
DOC)
Figure S3 NA alignment of all 2009 isolates tested here. Primers
designed to clone the entire NA gene were used to also sequence the
NA gene. Data was obtained for the entire NA gene except the region
corresponding to the first 27 and final 15 amino acids. Sequences
were aligned with Clustal W2software.Sequence data noted with N2
numbering scheme, as previously described [41]. Highlighted
residues correspond to: Red=N32, Green=I222, Blue=H274.
*=identical amino acid, : =highly similar amino acid, . =moder-
ately similar amino acid. Accession numbers for NA sequences
aligned here: A/St.Louis/790/2009=GQ994970 A/St.Louis/
764/2009=GQ994968 A/St.Louis/630/2009=GQ994964 A/
St.Louis/792/2009=GQ994971 A/St.Louis/775/2009=GQ994969
A/St.Louis/690/2009=GQ994965 A/St.Louis/539/2009=GQ-
994963 A/St.Louis/758/2009=GQ994967 A/St.Louis/746/
2009=GQ994966
Found at: doi:10.1371/journal.pone.0007838.s004 (0.04 MB
DOC)
Figure S4 NAalignmentofrecentlypublishedH1N1IFVisolates.
Published HAsequences for several 2007/2008 isolates were aligned
with Clustal W2 software to determine the conservation of amino
acid choice at select regions identified as mutations in Figure S1.
Sequence data noted with N2 numbering scheme, as previously
described [41]. Highlighted residues correspond to: Red=N32,
Green=I222, Blue=H274. *=identical amino acid, : =highly
similar amino acid, . =moderately similar amino acid. Accession
numbersforNAsequences alignedhere:A/Kentucky/UR06-0369/
2007=CY037665 A/Texas/UR06-0422/2007=CY037441 A/
Ohio/UR06-0493/2007=CY037657 A/NewJersey/15/2007=
EU516148 A/Perth/33/2008=FJ743472 A/Kentucky/UR07-
0061/2008=CY037697 A/Washington/AF06/2007=CY037329
A/Florida/UR07-0022/2008=CY037681 A/Hawaii/21/2007=
EU516112 A/Japan/AF07/2008=CY037337 A/Cambodia/21/
2007=FJ743470 A/Tennessee/UR06-0106/2007=CY037785 A/
Vermont/UR06-0513/2007=CY037465
Found at: doi:10.1371/journal.pone.0007838.s005 (0.05 MB
DOC)
Figure S5 HA alignment of all 2009 isolates tested here. Primers
designed to clone the entire HA gene were used to also sequence the
HA gene. Data was obtained for the entire HA gene except the
region corresponding to the first 25–31 and final 12 amino acids.
Sequences were aligned with Clustal W2 software. Sequence data
noted with H3 numbering scheme, as previously described [42].
Highlighted residues correspond to: Red=N163, Green=G/V189,
Blue=D225.*=identical amino acid,: =highlysimilar amino acid,
. =moderately similar amino acid. Poor data was obtained for
isolate 690 in region of first 100 amino acids so this sequence is
omitted from alignment comparison here. Accession numbers for
HA sequences aligned here: A/St.Louis/790/2009=GQ994961
A/St.Louis/764/2009=GQ994959 A/St.Louis/630/2009=GQ-
994955 A/St.Louis/792/2009=GQ994962 A/St.Louis/775/2009
=GQ994960 A/St.Louis/690/2009=GQ994956 A/St.Louis/
539/2009=GQ994954 A/St.Louis/758/2009=GQ994958 A/
St.Louis/746/2009=GQ994957
Found at: doi:10.1371/journal.pone.0007838.s006 (0.04 MB
DOC)
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PLoS ONE | www.plosone.org 7 November 2009 | Volume 4 | Issue 11 | e7838Figure S6 HA alignment of recently published H1N1 IFV isolates.
Published HA sequences for several 2007/2008 isolates were aligned
with Clustal W2 software to determine the conservation of amino
acid choice at select regions identified as mutations in Figure S3.
Sequence data noted with H3 numbering scheme, as previously
described [42]. Highlighted residues correspond to: Red=N163,
Green=G/V189, Blue=D225. *=identical amino acid, : =highly
similar amino acid, . =moderately similar amino acid. Accession
numbers for HA sequences aligned here: A/Kentucky/UR06-0369/
2007=CY037663 A/Texas/UR06-0422/2007=CY037439 A/
Ohio/UR06-0493/2007=CY037655 A/NewJersey/15/2007=
EU516083 A/Perth/33/2008=FJ743473 A/Kentucky/UR07-
0061/2008=CY037695 A/Washington/AF06/2007=CY037327
A/Florida/UR07-0022/2008=CY037679 A/Hawaii/21/2007=
EU516080 A/Japan/AF07/2008=CY037335 A/Cambodia/21/
2007=FJ743471 A/Tennessee/UR06-0106/2007=CY037783 A/
Vermont/UR06-0513/2007=CY037463 A/Charlottesville/31/
95=AF398878
Found at: doi:10.1371/journal.pone.0007838.s007 (0.05 MB
DOC)
Acknowledgments
We thank Eley K. Wong for assistance in cell culture and plaque reduction
assay quantification. We thank Mang Yu for critical evaluation of this
manuscript.
Author Contributions
Conceived and designed the experiments: GBTB LVG AIK RBM MH
JLL FF. Performed the experiments: GBTB. Analyzed the data: GBTB
LVG AIK MH JLL FF. Contributed reagents/materials/analysis tools:
AIK RB. Wrote the paper: GBTB DFW RBM FF.
References
1. World Health Organization (2009 April) Seasonal Influenza factsheet. http://
www.who.int/mediacentre/factsheets/fs211/en/index.html.
2. Dharan NJ, Gubareva LV, Meyer JJ, Okomo-Adhiambo M, McClinton RC,
et al. (2009) Infections with oseltamivir-resistant influenza A(H1N1) virus in the
United States. JAMA 301: 1034–1041.
3. Hatakeyama S, Sugaya N, Ito M, Yamazaki M, Ichikawa M, et al. (2007)
Emergence of influenza B viruses with reduced sensitivity to neuraminidase
inhibitors. JAMA 297: 1435–1442.
4. Hayden FG, Hay AJ (1992) Emergence and transmission of influenza A viruses
resistant to amantadine and rimantadine. Curr Top Microbiol Immunol 176:
119–130.
5. Moscona A (2005) Oseltamivir resistance–disabling our influenza defenses.
N Engl J Med 353: 2633–2636.
6. Moscona A (2009) Global transmission of oseltamivir-resistant influenza.
N Engl J Med 360: 953–956.
7. Sheu TG, Deyde VM, Okomo-Adhiambo M, Garten RJ, Xu X, et al. (2008)
Surveillance for neuraminidase inhibitor resistance among human influenza A
and B viruses circulating worldwide from 2004 to 2008. Antimicrob Agents
Chemother 52: 3284–3292.
8. Suzuki H, Saito R, Masuda H, Oshitani H, Sato M, et al. (2003) Emergence of
amantadine-resistant influenza A viruses: epidemiological study. J Infect Che-
mother 9: 195–200.
9. Zambon M, Hayden FG (2001) Position statement: global neuraminidase
inhibitor susceptibility network. Antiviral Res 49: 147–156.
10. Abdel-Ghafar AN, Chotpitayasunondh T, Gao Z, Hayden FG, Nguyen DH,
et al. (2008) Update on avian influenza A (H5N1) virus infection in humans.
N Engl J Med 358: 261–273.
11. de Jong MD, Tran TT, Truong HK, Vo MH, Smith GJ, et al. (2005)
Oseltamivir resistance during treatment of influenza A (H5N1) infection.
N Engl J Med 353: 2667–2672.
12. Gupta RK, Nguyen-Van-Tam JS (2006) Oseltamivir resistance in influenza A
(H5N1) infection. N Engl J Med 354: 1423–1424.
13. Gooskens J, Jonges M, Claas EC, Meijer A, van den Broek PJ, et al. (2009)
Morbidity and mortality associated with nosocomial transmission of oseltamivir-
resistant influenza A(H1N1) virus. JAMA 301: 1042–1046.
14. Hayden F (2009) Developing new antiviral agents for influenza treatment: what
does the future hold? Clin Infect Dis 48 Suppl 1: S3–13.
15. Malakhov MP, Aschenbrenner LM, Smee DF, Wandersee MK, Sidwell RW,
et al. (2006) Sialidase fusion protein as a novel broad-spectrum inhibitor of
influenza virus infection. Antimicrob Agents Chemother 50: 1470–1479.
16. Nicholls JM, Aschenbrenner LM, Paulson JC, Campbell ER, Malakhov MP,
et al. (2008) Comment on: concerns of using sialidase fusion protein as an
experimental drug to combat seasonal and pandemic influenza. J Antimicrob
Chemother 62: 426–428.
17. Ito T (2000) Interspecies transmission and receptor recognition of influenza A
viruses. Microbiol Immunol 44: 423–430.
18. Belser JA, Lu X, Szretter KJ, Jin X, Aschenbrenner LM, et al. (2007) DAS181, a
novel sialidase fusion protein, protects mice from lethal avian influenza H5N1
virus infection. J Infect Dis 196: 1493–1499.
19. CDC (2009) Update: drug susceptibility of swine-origin influenza A (H1N1)
viruses, April 2009. MMWR Morb Mortal Wkly Rep 58: 433–435.
20. Nelson MI, Viboud C, Simonsen L, Bennett RT, Griesemer SB, et al. (2008)
Multiple reassortment events in the evolutionary history of H1N1 influenza A
virus since 1918. PLoS Pathog 4: e1000012.
21. Gubareva LV, Matrosovich MN, Brenner MK, Bethell RC, Webster RG (1998)
Evidence for zanamivir resistance in an immunocompromised child infected
with influenza B virus. J Infect Dis 178: 1257–1262.
22. Ilyushina NA, Govorkova EA, Gray TE, Bovin NV, Webster RG (2008)
Human-like receptor specificity does not affect the neuraminidase-inhibitor
susceptibility of H5N1 influenza viruses. PLoS Pathog 4: e1000043.
23. Tisdale M (2000) Monitoring of viral susceptibility: new challenges with the
development of influenza NA inhibitors. Rev Med Virol 10: 45–55.
24. Kiso M, Sakai-Tagawa Y, Shiraishi K, Kawakami C, Kimura K, et al. (2004)
Resistant influenza A viruses in children treated with oseltamivir: descriptive
study. The Lancet 364: 759–765.
25. Abed Y, Bourgault AM, Fenton RJ, Morley PJ, Gower D, et al. (2002)
Characterization of 2 influenza A(H3N2) clinical isolates with reduced
susceptibility to neuraminidase inhibitors due to mutations in the hemagglutinin
gene. J Infect Dis 186: 1074–1080.
26. Baz M, Abed Y, McDonald J, Boivin G (2006) Characterization of multidrug-
resistant influenza A/H3N2 viruses shed during 1 year by an immunocompro-
mised child. Clin Infect Dis 43: 1555–1561.
27. Escuret V, Frobert E, Bouscambert-Duchamp M, Sabatier M, Grog I, et al.
(2008) Detection of human influenza A (H1N1) and B strains with reduced
sensitivity to neuraminidase inhibitors. J Clin Virol 41: 25–28.
28. Ison MG, Gubareva LV, Atmar RL, Treanor J, Hayden FG (2006) Recovery of
drug-resistant influenza virus from immunocompromised patients: a case series.
J Infect Dis 193: 760–764.
29. Gambaryan AS, Marinina VP, Tuzikov AB, Bovin NV, Rudneva IA, et al.
(1998) Effects of host-dependent glycosylation of hemagglutinin on receptor-
binding properties on H1N1 human influenza A virus grown in MDCK cells
and in embryonated eggs. Virology 247: 170–177.
30. Marinina VP, Gambarian AS, Bovin NV, Tuzikov AB, Shilov AA, et al. (2003)
[The effect of losing glycosylation sites near the receptor-binding region on the
receptor phenotype of the human influenza virus H1N1]. Mol Biol (Mosk) 37:
550–555.
31. Mishin VP, Novikov D, Hayden FG, Gubareva LV (2005) Effect of
hemagglutinin glycosylation on influenza virus susceptibility to neuraminidase
inhibitors. J Virol 79: 12416–12424.
32. Bao Y, Bolotov P, Dernovoy D, Kiryutin B, Zaslavsky L, et al. (2008) The
influenza virus resource at the National Center for Biotechnology Information.
J Virol 82: 596–601.
33. CDC (2009) Oseltamivir-Resistant 2009 Pandemic Influenza A (H1N1) Virus
Infection in Two Summer Campers Receiving Prophylaxis – North Carolina,
2009. MMWR Morb Mortal Wkly Rep 58: 969–972.
34. Hurt AC, Holien JK, Barr IG (2009) In vitro generation of neuraminidase
inhibitor resistance in A(H5N1) influenza viruses. Antimicrob Agents Che-
mother 53: 4433–4440.
35. Wang ZM, Tai CY, Mendel DB (2000) Characterisation of an influenza a virus
variant selected in vitro in the presence of the neuraminidase inhibitor, GS4071.
Antiviral Res 46:.
36. Tai CY, Escarpe PA, Sidwell RW, Williams MA, Lew W, et al. (1998)
Characterization of human influenza virus variants selected in vitro in the
presence of the neuraminidase inhibitor GS 4071. Antimicrob Agents
Chemother 42: 3234–3241.
37. Baum EZ, Wagaman PC, Ly L, Turchi I, Le J, et al. (2003) A point mutation in
influenza B neuraminidase confers resistance to peramivir and loss of slow
binding. Antiviral Res 59: 13–22.
38. Smee DF, Sidwell RW, Morrison AC, Bailey KW, Baum EZ, et al. (2001)
Characterization of an influenza A (H3N2) virus resistant to the cyclopentane
neuraminidase inhibitor RWJ-270201. Antiviral Res 52: 251–259.
39. Triana-Baltzer GB, Gubareva L, Nicholls JM, Pearce MB, Mishin VP, et al.
(2009) Novel Swine-Origin A(H1N1) Influenza Viruses are Potently Inhibited by
DAS181, a Sialidase Fusion Protein. PLoS ONE Manuscript in Review.
40. Hayden FG, Cote KM, Douglas RG Jr (1980) Plaque inhibition assay for drug
susceptibility testing of influenza viruses. Antimicrob Agents Chemother 17:
865–870.
41. Colman PM, Hoyne PA, Lawrence MC (1993) Sequence and structure
alignment of paramyxovirus hemagglutinin-neuraminidase with influenza virus
neuraminidase. J Virol 67: 2972–2980.
DAS181 Inhibits Resistant IFV
PLoS ONE | www.plosone.org 8 November 2009 | Volume 4 | Issue 11 | e783842. Winter G, Fields S, Brownlee GG (1981) Nucleotide sequence of the
haemagglutinin gene of a human influenza virus H1 subtype. Nature 292:
72–75.
43. DeLano WL (2002) The PyMOL Molecular Graphics System, version 0.99
[computer program]. DeLano Scientific.
DAS181 Inhibits Resistant IFV
PLoS ONE | www.plosone.org 9 November 2009 | Volume 4 | Issue 11 | e7838